$53.69
-1.86-3.35%
Últ. Act.: Nov 6, 6:43 PM
Cytokinetics (CYTK) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $-1.37 | $-1.42 | 3.52 % |
| Q2 | Aug 6, 2026 | $-1.50 | $-1.62 | 7.41 % |
| Q1 | May 5, 2026 | $-1.67 | $-1.65 | -1.21 % |
| Q4 | Feb 24, 2026 | $-1.50 | $-1.41 | -6.38 % |
Quarterly Revenue (Billions)
Cytokinetics (CYTK) publicó su última previsión de febrero 27, 2024 para fiscal year 2024. La compañía estimó ingresos en un rango de $3M - $5M para el período.
En comparación con la previsión anterior, Cytokinetics reducido redujo su previsión de ingresos desde un rango anterior de $5M - $5M.
Cytokinetics ha emitido 2 actualizaciones de orientación entre el marzo 1, 2023 y el febrero 27, 2024. During this period, the company lowered its outlook 1 time, signaling management's revised expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.42 | $-1.62 | $-1.65 | $-1.41 |
| Actual | $-1.37 | $-1.50 | $-1.67 | $-1.50 |
| Surprise | +3.52% | +7.41% | -1.21% | -6.38% |
| Revenue | ||||
| Estimate | $42.3M | $17.2M | $8.5M | $6.4M |
| Actual | $47.6M | $28.6M | $19.4M | $17.8M |
| Surprise | +12.5% | +66.0% | +128.1% | +178.7% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.41 | $-1.36 | $-1.38 | $-1.24 |
| Revenue | ||||
| Consensus | $63.4M | $69.4M | — | — |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $47.56M | $42.27M | 12.5 % |
| Q2 | Aug 6, 2026 | $28.62M | $17.24M | 66.0 % |
| Q1 | May 5, 2026 | $19.36M | $8.49M | 128.1 % |
| Q4 | Feb 24, 2026 | $17.76M | $6.37M | 178.7 % |